Publications - 'E'

Publications 751 - 775 de 2582
| % | ( | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | < | ? | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | [ | ` | {
Titre DOI
EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN INTERMEDIATE-HIGH RISK PULMONARY EMBOLISM: RESULTS FROM A MULTIDISCIPLINARY MULTICENTER PROSPECTIVE REGISTRY
R. Chopard; J.N. Andarelli; L. Cart; M. Badoz; F. Ecarnot; F. Schiele; N. Meneveau
2018 		10.1016/S0735-1097(18)32482-3
Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort
L. Piroth; L. Wittkop; K. Lacombe; E. Rosenthal; C. Gilbert; P. Miailhes; P. Carrieri; J. Chas; I. Poizot-Martin; A. Gervais; S. Dominguez; D. Neau; D. Zucman; E. Billaud; P. Morlat; H. Aumaitre; C. Lascoux-Combe; A. Simon; O. Bouchaud; E. Teicher; F. Bani-Sadr; L. Alric; D. Vittecoq; F. Boue; C. Duvivier; M.A. Valantin; L. Esterle; F. Dabis; P. Sogni; D. Salmon; A.N.R.S.C.O.13 H.E.P.A.V. Grp
2017 		10.1016/j.jhep.2017.02.012
Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial
F. Saliba; C. Duvoux; J. Gugenheim; N. Kamar; S. Dharancy; E. Salame; M. Neau-Cransac; F. Durand; P. Houssel-Debry; C. Vanlemmens; G. Pageaux; J. Hardwigsen; D. Eyraud; Y. Calmus; F. Di Giambattista; J. Dumortier; F. Conti
2017 		10.1111/ajt.14212
EFFICACY AND SAFETY OF HFVIII/VWF (VONCENTO (R)) CONCENTRATE IN PAEDIATRIC PATIENTS WITH VON WILLEBRAND DISEASE (VWD): THE FRENCH EXPERIENCE
A. Harroche; L. Rugeri; R. D'Oiron; A. Hassoun; Y. Repesse; B. Frotscher; A. Fournel; D. Bracquart; C. Martin; M. Trossaert; S. Meunier
2021
EFFICACY AND SAFETY OF HIGH RATIO HVWF/FVIII CONCENTRATE (VONCENTO (R)) FOR THE TREATMENT OF BLEEDING EPISODES IN PATIENTS WITH VON WILLEBRAND DISEASE: THE OPALE FRENCH EXPERIENCE
R. D'Oiron; L. Rugeri; A. Harroche; A. Fournel; A. Hassoun; S. Combe; S. Castet; V. Proulle; D. Desprez; E. De Raucourt; D. Bracquart; H. Catovic; C. Martin; M. Trossaert; B. Guillet
2022
Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy
M. Severino; L. Simioni; P. Bonadonna; R. Cantone; G. Cortellini; S. Crescioli; A. D'Angelo; L. La Rosa; D. Macchia; I. Martignago; A. Massolo; F. Reccardini; D. Bagnasco; G. Passalacqua
2019 		10.1016/j.waojou.2019.100086
Efficacy and safety of hydrolyzed rice-protein formulas for the treatment of cow's milk protein allergy
A. Bocquet; C. Dupont; J.P. Chouraqui; D. Darmaun; F. Feillet; M.L. Frelut; J.P. Girardet; R. Hankard; A. Lapillonne; J.C. Roze; U. Simeoni; D. Turck; A. Briend; C.Nutr Frenc CNSFP
2019 		10.1016/j.arcped.2019.03.001
Efficacy and Safety of hypofractionated loco-regional radiotherapy for breast cancer patients.
M. Caubet; P. Bontemps; A. Anota; F. Boulbair; Y. Hammoud; K. Peigneaux; G. Crehange; B. De Bari
2018 		10.1016/S0167-8140(18)31645-1
Efficacy and Safety of Immunosuppressive Therapy with Horse Antithymocyte Globulin (ATGAM) Plus Ciclosporine in 341 Patients with Acquired Aplastic Anemia: Report of the French Patient-Named Program on Behalf of the French Reference Center for Aplastic An
R.Peffault de Latour; R. Tabrizi; F. Suarez; T. Lamy; M. Mohty; C. Recher; C. Jubert; M. Pasquet; C. Galambrun; S. Nguyen; J.Y. Cahn; T. Brawn; E. Deconinck; J.O. Bay; F. Barraco; G. Socie
2016
Efficacy and safety of infliximab retreatment in luminal Crohn's disease: a multi-centre, prospective, observational cohort (REGAIN) study
G. Boschetti; B. Pariente; D. Laharie; X. Roblin; C. Gilletta; A. Aubourg; A. Bourreille; C. Zallot; X. Hebuterne; A. Buisson; J.C. Grimaud; Y. Bouhnik; M. Allez; R. Altwegg; S. Viennot; L. Vuitton; F. Carbonnel; M. Nachury; S. Paul; J. Lambert; L. Peyrin-Biroulet; GETAID
2019 		10.1093/ecco-jcc/jjy222.838
Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial
J. Hogan; A. Perez; A.L. Sellier-Leclerc; I. Vrillon; F. Broux; F. Nobili; J. Harambat; L. Bessenay; V. Audard; C. Faudeux; D. Morin; C. Pietrement; S. Tellier; D. Djeddi; P. Eckart; A. Lahoche; G. Roussey-Kesler; T. Ulinski; O. Boyer; E. Plaisier; S. Cloarec; A. Jolivot; V. Guigonis; S. Guilmin-Crepon; V. Baudouin; C. Dossier; G. Deschenes
2020 		10.1136/bmjopen-2020-037306
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
M.S. Capehorn; A.M. Catarig; J.K. Furberg; A. Janez; H.C. Price; S. Tadayon; B. Verges; M. Marre
2020 		10.1016/j.diabet.2019.101117
Efficacy and safety of prophylaxis with recombinant von Willebrand factor (VWF) in severe von Willebrand disease (VWD): Design of a prospective, phase 3, open-label, international multicenter study
F.W. Leebeek; K. Kavakli; F. Genre-Volot; F. Peyvandi; W. Miesbach; A. Shapiro; M. Timofeeva; L. Martell; S. Abrol; G. Ozen; B. Mellgard
2019
Efficacy and safety of ramucirumab (RAM) for advanced hepatocellular carcinoma (HCC) with elevated alpha-fetoprotein (AFP) following first-line sorafenib across age subgroups in two global phase III trials (REACH and REACH-2)
M. Kudo; P.R. Galle; K. Motomura; E. Assenat; P. Merle; G. Brandi; B. Daniele; T. Okusaka; J. Tomasek; C. Borg; V. Zagonel; M. Morimoto; M. Pracht; R.S. Finn; J. Llovet; G. Homma; M.H. Jen; K. Shinozaki; R. Yoshikawa; A.X. Zhu
2019
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
F. Duffaud; O. Mir; P. Boudou-Rouquette; S. Piperno-Neumann; N. Penel; E. Bompas; C. Delcambre; E. Kalbacher; A. Italiano; O. Collard; C. Chevreau; E. Saada; N. Isambert; J. Delaye; C. Schiffler; C. Bouvier; V. Vidal; S. Chabaud; J.Y. Blay; F.Sarcoma Grp
2019 		10.1016/S1470-2045(18)30742-3
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study
F. Duffaud; A. Italiano; E. Bompas; M. Rios; N. Penel; O. Mir; S. Piperno-Neumann; C. Chevreau; C. Delcambre; F. Bertucci; P. Boudou-Rouquette; M. Cancel; C. Perrin; E. Saada-Bouzid; L. Monard; C. Schiffler; L. Chaigneau; A. Hervieu; O. Collard; C. Bouvier; V. Vidal; S. Chabaud; J.Y. Blay; F.Sarcoma Grp
2021 		10.1016/j.ejca.2021.03.039
Efficacy and safety of retreatment with Elbasvir/Grazoprevir associated to Sofosbuvir plus /- Ribavirin in HCV infected patients with a previous failure to therapy with direct-acting antiviral drugs
L. Alric; V. Leroy; L. Cotte; M. Anne; A.Jean Remy; I. Rouanet; M. Godart; C. Hezode; F. Abravanel; I. Ollivier-Hourmand
2017
Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in MONALEESA-2
G.S. Sonke; L.L. Hart; M. Campone; F. Erdkamp; W. Janni; S. Verma; C. Villanueva; E. Jakobsen; E. Alba; E. Wist; A.M. Favret; T. Bachelot; R. Hegg; P. Wheatley-Price; F. Souami; S. Sutradhar; M. Miller; C. Germa; H.A. Burris
2017 		10.1016/S0959-8049(17)30091-6
Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in MONALEESA-2
G.S. Sonke; L.L. Hart; M. Campone; F. Erdkamp; W. Janni; S. Verma; C. Villanueva; E. Jakobsen; E. Alba; E. Wist; A.M. Favret; T. Bachelot; R. Hegg; P. Wheatley-Price; F. Souami; S. Sutradhar; M. Miller; C. Germa; H.A. Burris
2017
Efficacy and Safety of Rituximab in Hepatitis B Virus-Associated PLA2R-Positive Membranous Nephropathy
L. Berchtold; G. Zanetta; K. Dahan; F. Mihout; J. Peltier; D. Guerrot; I. Brocheriou; P. Ronco; H. Debiec
2018 		10.1016/j.ekir.2017.09.009
Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study
M. Ferreira; R. Borie; B. Crestani; P. Rigaud; L. Wemeau; D. Israel-Biet; S. Leroy; S. Quetant; L. Plantier; J.C. Dalphin; V. Cottin; S. Marchand-Adam; O.L. Network
2020 		10.1016/j.rmed.2020.106146
EFFICACY AND SAFETY OF RVWF PROPHYLAXIS IN SEVERE VON WILLEBRAND DISEASE: PROSPECTIVE, OPEN, INTERNATIONAL, MULTICENTRE PHASE III STUDY
F.W.G. Leebeek; K. Kavakli; F. Genre-Volot; F. Peyvandi; W. Miesbach; A. Shapiro; M. Timofeeva; I. Vidal; L. Martell; S. Abrol; G. Ozen; B. Mellgard
2019
Efficacy and safety of semaglutide 1.0 mg once weekly vs liraglutide 1.2 mg once daily as add-on to 1-3 oral glucose-lowering drugs in subjects with type 2 diabetes (SUSTAIN 10)
M.S. Capehorn; A.M. Catarig; J.K. Furberg; A. Janez; H.C. Price; S. Tadayon; B. Verges; M. Marre
2019
Efficacy and safety of semaglutide 1.0mg once weekly vs liraglutide 1.2mg once daily as add-on to 1-3 oral antidiabetic drugs in subjects with Type 2 diabetes (SUSTAIN 10)
M. Capehorn; A. Janez; H. Price; B. Verges; A.M. Catarig; K. Furberg; S. Tadayon; M. Marre
2019
Efficacy and safety of semaglutide 1.0mg once weekly vs liraglutide 1.2mg once daily as add-on to 1-3 oral antidiabetic drugs in subjects with Type 2 diabetes (SUSTAIN 10)
M. Capehorn; A. Janez; H. Price; B. Verges; A.M. Catarig; K. Furberg; S. Tadayon; M. Marre
2019

Pages